Pleiotrophic and anti-inflammatory effects of pioglitazone precede the metabolic activity in type 2 diabetic patients with coronary artery disease

Atherosclerosis

Volumn 197, Issue 1, 2008, Pages 311-317

  Forst, T ^a   Karagiannis, E ^a   Lubben G ^a   Hohberg, C ^a   Schondorf T ^a   Dikta, G ^a   Drexler, M ^a   Morcos, M ^a   Danschel W ^a   Borchert, M ^a   Pfutzner A ^a  

^a Institute for Clinical Research and Development   (Germany)

Author keywords

Cardiovascular disease; Inflammation; Metalloproteinases; PPAR agonists; Type 2 diabetes mellitus

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; CD40 ANTIGEN; CHOLESTEROL; GELATINASE B; GLITAZONE DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PADGEM PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLACEBO; PROINSULIN; SULFONYLUREA; TRIACYLGLYCEROL;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEMOGRAPHY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; FEMALE; GLUCOSE METABOLISM; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PLEIOTROPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL ANALYSIS; WEIGHT GAIN;

AGED; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PLACEBOS; THIAZOLIDINEDIONES; VASCULITIS;

EID: 39449138164     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2007.05.006     Document Type: Article

References (49)

1. Libby P., Schoenbeck U., Mach F., Selwyn A.P., and Ganz P. Current concepts in cardiovascular pathology: the role of LDL cholesterol in plaque rupture and stabilization. Am J Med 104 (1998) 14S-18S
2. Loftus I.M., Naylor A.R., Goodall S., et al. Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. Stroke 31 (2000) 40-47
3. Loftus I.M., Naylor A.R., Bell P.R., and Thompson M.M. Matrix metalloproteinases and atherosclerotic plaque instability. Br J Surg 89 (2002) 680-694
4. Dollery C.M., McEwan J.R., and Henney A.M. Matrix metalloproteinases and cardiovascular disease. Circ Res 77 (1995) 863-868
5. Kai H., Ikeda H., Yasukawa H., et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 32 (1998) 368-372
6. Marx N., Froehlich J., Siam L., et al. Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 23 (2003) 283-288
7. Moreno P.R., Murcia A.M., Palacios I.F., et al. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation 102 (2000) 2180-2184
8. Vorchheimer D.A., and Fuster V. Inflammatory markers in coronary artery disease: let prevention douse the flames. JAMA 286 (2001) 2154-2156
9. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., and Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336 (1997) 973-979
10. Guzik T.J., Mangalat D., and Korbut R. Adipocytokines-novel link between inflammation and vascular function?. J Physiol Pharmacol 57 (2006) 505-528
11. Festa A., D'Agostino Jr. R., Howard G., et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102 (2000) 42-47
12. Arroyo-Espliguero R., Avanzas P., Cosin-Sales J., et al. C-reactive protein elevation and disease activity in patients with coronary artery disease. Eur Heart J 25 (2004) 401-408
13. Schulze M.B., Rimm E.B., Shai I., Rifai N., and Hu F.B. Relationship between adiponectin and glycemic control, blood lipids, and inflammatory markers in men with type 2 diabetes. Diabetes Care 27 (2004) 1680-1687
14. Pischon T., Girman C.J., Hotamisligil G.S., et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291 (2004) 1730-1737
15. Zethelius B., Lithell H., Hales C.N., and Berne C. Insulin sensitivity, proinsulin and insulin as predictors of coronary heart disease. A population-based 10-year, follow-up study in 70-year-old men using the euglycaemic insulin clamp. Int J Obes Relat Metab Disord 48 (2005) 862-867
16. Alssema M., Dekker J.M., Nijpels G., et al. Proinsulin concentration is an independent predictor of all-cause and cardiovascular mortality: an 11-year follow-up of the Hoorn Study. Diabetes Care 28 (2005) 860-865
17. Miyazaki Y., Mahankali A., Matsuda M., et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 24 (2001) 710-719
18. Aronoff S., Rosenblatt S., Braithwaite S., et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 23 (2000) 1605-1611
19. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 351 (2004) 1106-1118
20. Hanefeld M., Marx N., Pfutzner A., et al. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. J Am Coll Cardiol 49 (2007) 290-297
21. Ghanim H., Dhindsa S., Aljada A., et al. Low-dose rosiglitazone exerts an antiinflammatory effect with an increase in adiponectin independently of free fatty acid fall and insulin sensitization in obese type 2 diabetics. J Clin Endocrinol Metab 91 (2006) 3553-3558
22. Esposito K., Ciotola M., Carleo D., et al. Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. Diabetes Care 29 (2006) 1071-1076
23. Horio T., Suzuki M., Takamisawa I., et al. Pioglitazone-induced insulin sensitization improves vascular endothelial function in nondiabetic patients with essential hypertension. Am J Hypertens 18 (2005) 1626-1630
24. Sourij H., Zweiker R., and Wascher T.C. Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes. Diabetes Care 29 (2006) 1039-1045
25. Pfutzner A., Schneider C.A., and Forst T. Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects. Expert Rev Cardiovasc Ther 4 (2006) 445-459
26. Pfutzner A., and Forst T. Pioglitazone: an antidiabetic drug with the potency to reduce cardiovascular mortality. Expert Opin Pharmacother 7 (2006) 463-476
27. Satoh N., Ogawa Y., Usui T., et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 26 (2003) 2493-2499
28. Pistrosch F., Passauer J., Fischer S., et al. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care 27 (2004) 484-490
29. van Doorn M., Kemme M., Ouwens M., et al. Evaluation of proinflammatory cytokines and inflammation markers as biomarkers for the action of thiazolidinediones in type 2 diabetes mellitus patients and healthy volunteers. Br J Clin Pharmacol 62 (2006) 391-402
30. Hedblad B., Nilsson P., Janzon L., and Berglund G. Relation between insulin resistance and carotid intima-media thickness and stenosis in non-diabetic subjects. Results from a cross-sectional study in Malmo, Sweden. Diabet Med 17 (2000) 299-307
31. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
32. Forst T., Hohberg C., Fuellert S.D., et al. Pharmacological PPARgamma stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetes. Horm Metab Res 37 (2005) 521-527
33. Pfutzner A., Marx N., Lubben G., et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 45 (2005) 1925-1931
34. Marx N., Imhof A., Froehlich J., et al. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation 107 (2003) 1954-1957
35. Haffner S.M., Greenberg A.S., Weston W.M., et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106 (2002) 679-684
36. Mazzone T., Meyer P.M., Feinstein S.B., et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 296 (2006) 2572-2581
37. Dormandy J.A., Charbonnel B., Eckland D.J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
38. Langenfeld M.R., Forst T., Hohberg C., et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 111 (2005) 2525-2531
39. Martens F.M., Visseren F.L., de Koning E.J., and Rabelink T.J. Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes. J Cardiovasc Pharmacol 46 (2005) 773-778
40. Forst T., Lubben G., Hohberg C., et al. Influence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mellitus type 2. Microcirculation 12 (2005) 543-550
41. Nolan J.J., Ludvik B., Beerdsen P., Joyce M., and Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331 (1994) 1188-1193
42. Patel J., Anderson R.J., and Rappaport E.B. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study. Diabetes Obes Metab 1 (1999) 165-172
43. Lam K.S., and Xu A. Adiponectin: protection of the endothelium. Curr Diab Rep 5 (2005) 254-259
44. Hotta K., Funahashi T., Arita Y., et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20 (2000) 1595-1599
45. Maahs D.M., Ogden L.G., Kinney G.L., et al. Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation 111 (2005) 747-753
46. Schulze M.B., Shai I., Rimm E.B., et al. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 54 (2005) 534-539
47. Haffner S.M., D'Agostino R., Mykkanen L., et al. Proinsulin and insulin concentrations in relation to carotid wall thickness: Insulin Resistance Atherosclerosis Study. Stroke 29 (1998) 1498-1503
48. Pfutzner A., Kunt T., Hohberg C., et al. Fasting intact proinsulin is a highly specific predictor of insulin resistance in type 2 diabetes. Diabetes Care 27 (2004) 682-687
49. Yudkin J.S., May M., Elwood P., et al. Concentrations of proinsulin like molecules predict coronary heart disease risk independently of insulin: prospective data from the Caerphilly Study. Diabetologia 45 (2002) 327-336